Filed: 10/30/2023ACC: 0001104659-23-112611
📋 What this filing means
RIVERVEST VENTURE MANAGEMENT LLC filed this quarterly 13F‑HR report disclosing 5 equity positions with a total reported market value of $40.43M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
5
Positions
$40.43M
Total AUM (reported)
11.95M
Total Shares
Allocation by class
COMMON$40.43M100.0%
Portfolio Concentration
Top 3$37.26M92.1%
4–10$3.17M7.9%
Top 3 weight
92.1%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 11.95M
Sole
Full voting authority
10.26M
shares
% of voting shares85.9%
Shared
Joint voting authority
1.69M
shares
% of voting shares14.1%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole3
Shared0
Other2
Dominant voting typeSole · 85.9% of voting shares
Institutional Holdings5
Rows:
Reneo Pharmaceuticals, Inc.
SOLEShares2.53M
TypeSH
Market value$19.30M
47.73%
Sole
2.53M
Shared
0.00
None
0.00
Allakos, Inc.
OTRShares4.99M
TypeSH
Market value$11.32M
28.00%
Sole
3.35M
Shared
1.64M
None
0.00
Spruce Bioscience, Inc.
SOLEShares2.94M
TypeSH
Market value$6.64M
16.41%
Sole
2.94M
Shared
0.00
None
0.00
Xilio Therapeutics, Inc.
SOLEShares1.44M
TypeSH
Market value$3.04M
7.52%
Sole
1.44M
Shared
0.00
None
0.00
Vapotherm, Inc.
OTRShares52.55K
TypeSH
Market value$133.0K
0.33%
Sole
0.00
Shared
52.55K
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Reneo Pharmaceuticals, Inc.SOLE | Common | 2.53M | SH | $19.30M 47.73% | 2.53M | 0.00 | 0.00 |
Allakos, Inc.OTR | Common | 4.99M | SH | $11.32M 28.00% | 3.35M | 1.64M | 0.00 |
Spruce Bioscience, Inc.SOLE | Common | 2.94M | SH | $6.64M 16.41% | 2.94M | 0.00 | 0.00 |
Xilio Therapeutics, Inc.SOLE | Common | 1.44M | SH | $3.04M 7.52% | 1.44M | 0.00 | 0.00 |
Vapotherm, Inc.OTR | Common | 52.55K | SH | $133.0K 0.33% | 0.00 | 52.55K | 0.00 |